GSK lays out Japan launch plans
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline is anticipating the approval of three new molecular entities (NMEs) in Japan this calendar year, the same number it received in 2013, with the biggest commercial opportunity in patient number terms being the combination therapy for chronic obstructive pulmonary disease (COPD) umeclidinium plus vilanterol.